- Report
- August 2026
- 187 Pages
Global
From €5248EUR$5,850USD£4,486GBP
- Report
- August 2026
- 216 Pages
Global
From €5248EUR$5,850USD£4,486GBP
- Report
- August 2026
- 411 Pages
Global
From €5248EUR$5,850USD£4,486GBP
- Report
- November 2025
- 200 Pages
Global
From €7132EUR$7,950USD£6,097GBP
- Report
- July 2026
- 185 Pages
Global
From €4261EUR$4,750USD£3,643GBP
- Report
- May 2026
- 140 Pages
Global
From €4261EUR$4,750USD£3,643GBP
- Report
- May 2026
- 350 Pages
Global
From €4440EUR$4,949USD£3,795GBP
- Report
- May 2026
- 145 Pages
Global
From €3543EUR$3,950USD£3,029GBP
- Report
- May 2026
- 158 Pages
Global
From €3543EUR$3,950USD£3,029GBP
- Report
- May 2026
- 148 Pages
Global
From €3543EUR$3,950USD£3,029GBP
- Report
- September 2025
- 150 Pages
Global
From €4351EUR$4,850USD£3,719GBP
- Report
- January 2026
- 160 Pages
Global
From €2835EUR$3,160USD£2,423GBP
€3543EUR$3,950USD£3,029GBP
- Report
- July 2026
- 160 Pages
Global
From €3723EUR$4,150USD£3,183GBP
- Report
- July 2026
- 160 Pages
Global
From €3723EUR$4,150USD£3,183GBP
- Report
- February 2026
- 160 Pages
Global
From €2978EUR$3,320USD£2,546GBP
€3723EUR$4,150USD£3,183GBP
- Report
- November 2025
- 160 Pages
Global
From €2835EUR$3,160USD£2,423GBP
€3543EUR$3,950USD£3,029GBP
- Report
- October 2025
- 160 Pages
Global
From €2835EUR$3,160USD£2,423GBP
€3543EUR$3,950USD£3,029GBP
- Report
- October 2025
- 160 Pages
Global
From €2835EUR$3,160USD£2,423GBP
€3543EUR$3,950USD£3,029GBP
- Report
- February 2026
- 191 Pages
Global
From €4351EUR$4,850USD£3,719GBP
- Report
- December 2025
- 150 Pages
Global
From €4351EUR$4,850USD£3,719GBP

The CAS9 market is a subset of the genomics industry that focuses on the development and use of the CRISPR-Cas9 gene-editing technology. This technology is used to modify the genetic code of living organisms, allowing for the manipulation of genes and the potential to create new treatments for diseases. CAS9 is a powerful tool for researchers, allowing them to make precise changes to the genetic code of organisms.
The CAS9 market is growing rapidly, with many companies investing in the technology and its applications. Companies such as Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics, and Caribou Biosciences are leading the way in developing and commercializing the technology. Other companies such as Horizon Discovery, Synthego, and Twist Bioscience are also investing in the CAS9 market, providing tools and services to researchers. Show Less Read more